Рівень насіннєвої продуктивності і морфологічні особливості насіння деяких видів і сортів роду Tulipa L.

We have given the data on the setting of seeds of different species and varieties of the tulips of different classes, as well as on the mass of 1000 seeds, length of their germs and the seeds of certain species and varieties of the collection of the N.N. Grishko National Botanical Gardens by the name of the National Academy of Sciences of Ukraine. It has been found out that the average production of the species seeds of the tulips is higher than that of the varieties, but the tulips varieties are characterized by the higher mass and the longer length of the seed.Наведено дані стосовно зав’язування насіння видами і сортами тюльпанів різних класів, а також відомості про м асу 1000 шт. насінин, довжину зародка і насіння деяких видів і сортів колекції Національного ботанічного саду ім. М.М. Гришка НАН України. Виявлено, що середня насіннєва продуктивність у видів тюльпанів вища, ніж у сортів, але сортові тюльпани характеризуються більшою масою і довжиною насіння

FREQUENCY OF SIDE EFFECTS OF ANTIVIRUS THERAPY FOR CHRONIC VIRUS HEPATITIS IN CHILDHOOD

In pediatrics, the issue of using antivirus therapy for chronic virus hepatitis is not sufficiently studied, there is search for rational combinations, schemes, doses and length of treatment. The article demonstrates results of using a combined antivirus therapy with alpha interferon medications, interferon inducers, systemic enzymotherapy in children with chronic virus hepatitis B and C. Including systemic enzymotherapy medications in the combined treatment made it possible to reduce the number and severity of side effects of parenteral interferons. Key words: chronic hepatitis, antivirus therapy, alpha interferon, interferon inducers, children. (Pediatric Pharmacology. – 2010; 7(2):73-77

FREQUENCY OF SIDE EFFECTS OF ANTIVIRUS THERAPY FOR CHRONIC VIRUS HEPATITIS IN CHILDHOOD

In pediatrics, the issue of using antivirus therapy for chronic virus hepatitis is not sufficiently studied, there is search for rational combinations, schemes, doses and length of treatment. The article demonstrates results of using a combined antivirus therapy with alpha interferon medications, interferon inducers, systemic enzymotherapy in children with chronic virus hepatitis B and C. Including systemic enzymotherapy medications in the combined treatment made it possible to reduce the number and severity of side effects of parenteral interferons. Key words: chronic hepatitis, antivirus therapy, alpha interferon, interferon inducers, children. (Pediatric Pharmacology. – 2010; 7(2):73-77

ЧАСТОТА ПОБОЧНЫХ ЭФФЕКТОВ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ХРОНИЧЕСКИХ ВИРУСНЫХ ГЕПАТИТОВ В ДЕТСКОМ ВОЗРАСТЕ

In pediatrics, the issue of using antivirus therapy for chronic virus hepatitis is not sufficiently studied, there is search for rational combinations, schemes, doses and length of treatment. The article demonstrates results of using a combined antivirus therapy with alpha interferon medications, interferon inducers, systemic enzymotherapy in children with chronic virus hepatitis B and C. Including systemic enzymotherapy medications in the combined treatment made it possible to reduce the number and severity of side effects of parenteral interferons. Key words: chronic hepatitis, antivirus therapy, alpha interferon, interferon inducers, children. (Pediatric Pharmacology. – 2010; 7(2):73-77)В педиатрии вопрос применения противовирусной терапии при хронических вирусных гепатитах не достаточно изучен, продолжаются поиски рациональных комбинаций, схем, доз и длительности лечения. В статье представлены результаты применения комбинированной противовирусной терапии с использованием препаратов альфа-интерферона, индукторов интерферона, препаратов системной энзимотерапии у детей с хроническими вирусными гепатитами В и С. Ключевые слова: хронический гепатит, противовирусная терапия, интерферон ?, индукторы интерферона, дети. (Педиатрическая фармакология. – 2010; 7(2):73-77

Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial

Background: Non-immunogenic staphylokinase is modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity, and selectivity to fibrin. We aimed to assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with acute ischaemic stroke within 4·5 h after symptom onset. Methods: We did a randomised, open-label, multicentre, parallel-group, non-inferiority trial in 18 clinical sites in Russia. We included patients aged 18 years and older with a diagnosis of acute ischaemic stroke (up to 25 points on the National Institutes of Health Stroke Scale). The study drug had to be administered within 4·5 h after the onset of symptoms. Patients were randomly assigned to receive either non-immunogenic staphylokinase (10 mg) or alteplase (0·9 mg/kg, maximum 90 mg), both administered intravenously. The randomisation sequence was created by an independent biostatistician using computer-generated random numbers. 84 blocks (block size of four) of opaque sealed envelopes were numbered sequentially from 1 to 336 and were opened in numerical order. Patients were unaware of their assigned treatment and were assessed by the study investigators who were also unaware of the treatment assignment on all trial days. Emergency department staff, who administered the assigned drug and opened the envelopes, were not masked to treatment. The primary efficacy endpoint was a favourable outcome, defined as a modified Rankin scale (mRS) score of 0–1 on day 90. The margin of non-inferiority was established as 16% for the difference in mRS score of 0–1 on day 90. Non-inferiority was tested using Welch's t-test for the primary outcome only. Endpoints were analysed in the per-protocol population, which comprised all randomly assigned patients who completed treatment without any protocol violations; this population was identical to the intention-to-treat population. This trial is completed and registered at ClinicalTrials.gov, NCT03151993. Findings: Of 385 patients recruited from March 18, 2017, to March 23, 2019, 336 (87%) were included in the trial. 168 (50%) patients were randomly assigned to receive non-immunogenic staphylokinase and 168 (50%) to receive alteplase. The median duration of follow-up was 89 days (IQR 89–89). 84 (50%) of 168 patients in the non-immunogenic staphylokinase group had a favourable outcome at day 90 compared with 68 (40%) of 168 patients in the alteplase group (odds ratio [OR] 1·47, 95% CI 0·93 to 2·32; p=0·10). The difference in the rate of favourable outcome at day 90 was 9·5% (95% CI –1·7 to 20·7) and the lower limit did not cross the margin of non-inferiority (pnon-inferiority <0·0001). Symptomatic intracranial haemorrhage occurred in five (3%) patients in the non-immunogenic staphylokinase group and in 13 (8%) patients in the alteplase group (p=0·087). On day 90, 17 (10%) patients in the non-immunogenic staphylokinase group and 24 (14%) patients in the alteplase group had died (p=0·32). 22 (13%) patients in the non-immunogenic staphylokinase group had serious adverse events, compared with 37 (22%) patients in the alteplase group (p=0·044). Interpretation: Non-immunogenic staphylokinase was non-inferior to alteplase for patients with acute ischaemic stroke. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ significantly between groups. Future studies are needed to continue to assess the safety and efficacy of non-immunogenic staphylokinase in patients with acute ischaemic stroke within the 4·5 h time window, and to assess the drug in patients with acute ischaemic stroke outside this time window with reperfusion CT or magnetic resonance angiography followed by thrombectomy if necessary. Funding: The Russian Academy of Sciences. © 2021 Elsevier Lt